MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

No Stability Information

Arginine 500mg tablets (Special Order)

Explore other Arginine formulations Explore other Arginine 500mg tablets suppliers

Stability Notes

There are no stability notes available for this medicine.

No Stability Information

Arginine hydrochloride 1.25g capsules (Special Order)

Explore other Arginine formulations Explore other Arginine hydrochloride 1.25g capsules suppliers

Stability Notes

There are no stability notes available for this medicine.

Compatible

Aricept 10mg tablets (Eisai Ltd)

Explore other Donepezil formulations Explore other Donepezil 10mg tablets suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Aricept 10mg tablets (Eisai Ltd).

Compatible

Aricept 10mg tablets (Sigma Pharmaceuticals Plc)

Explore other Donepezil formulations Explore other Donepezil 10mg tablets suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Aricept 10mg tablets (Eisai Ltd).

Compatible

Aricept 5mg tablets (Eisai Ltd)

Explore other Donepezil formulations Explore other Donepezil 5mg tablets suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Aricept 5mg tablets (Eisai Ltd).

Compatible

Aricept 5mg tablets (Sigma Pharmaceuticals Plc)

Explore other Donepezil formulations Explore other Donepezil 5mg tablets suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Aricept 5mg tablets (Eisai Ltd).

Incompatible

Aricept Evess 10mg orodispersible tablets (Eisai Ltd)

Explore other Donepezil formulations Explore other Donepezil 10mg orodispersible tablets sugar free suppliers

Stability Notes

Not suitable for MCA because it is an orodispersible tablet.

Provenance

This compatibility recommendation is derived from Aricept Evess 10mg orodispersible tablets (Eisai Ltd).

Incompatible

Aricept Evess 10mg orodispersible tablets (Sigma Pharmaceuticals Plc)

Explore other Donepezil formulations Explore other Donepezil 10mg orodispersible tablets sugar free suppliers

Stability Notes

Not suitable for MCA because it is an orodispersible tablet.

Provenance

This compatibility recommendation is derived from Aricept Evess 10mg orodispersible tablets (Eisai Ltd).

Incompatible

Aricept Evess 5mg orodispersible tablets (Eisai Ltd)

Explore other Donepezil formulations Explore other Donepezil 5mg orodispersible tablets sugar free suppliers

Stability Notes

Not suitable for MCA because it is an orodispersible tablet.

Provenance

This compatibility recommendation is derived from Aricept Evess 5mg orodispersible tablets (Eisai Ltd).

Compatible

Arimidex 1mg tablets (AstraZeneca UK Ltd)

Explore other Anastrozole formulations Explore other Anastrozole 1mg tablets suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Arimidex 1mg tablets (AstraZeneca UK Ltd).

Compatible

Arimidex 1mg tablets (Lexon (UK) Ltd)

Explore other Anastrozole formulations Explore other Anastrozole 1mg tablets suppliers

Stability Notes

No special precautions for storage.

Provenance

This compatibility recommendation is derived from Arimidex 1mg tablets (AstraZeneca UK Ltd).

Incompatible

Aripiprazole 10mg orodispersible tablets sugar free (A A H Pharmaceuticals Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 10mg orodispersible tablets sugar free suppliers

Stability Notes

Protect from moisture. Orodispersible in nature therefore likely to be hygroscopic.

Provenance

This compatibility recommendation is derived from Abilify 10mg orodispersible tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Incompatible

Aripiprazole 10mg orodispersible tablets sugar free (Accord-UK Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 10mg orodispersible tablets sugar free suppliers

Stability Notes

Protect from moisture. Orodispersible in nature therefore likely to be hygroscopic.

Provenance

This compatibility recommendation is derived from Abilify 10mg orodispersible tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Incompatible

Aripiprazole 10mg orodispersible tablets sugar free (Alliance Healthcare (Distribution) Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 10mg orodispersible tablets sugar free suppliers

Stability Notes

Protect from moisture. Orodispersible in nature therefore likely to be hygroscopic.

Provenance

This compatibility recommendation is derived from Abilify 10mg orodispersible tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Incompatible

Aripiprazole 10mg orodispersible tablets sugar free (Colorama Pharmaceuticals Ltd)

Explore other Aripiprazole formulations Explore other Aripiprazole 10mg orodispersible tablets sugar free suppliers

Stability Notes

Protect from moisture. Orodispersible in nature therefore likely to be hygroscopic.

Provenance

This compatibility recommendation is derived from Abilify 10mg orodispersible tablets (Otsuka Pharmaceuticals (U.K.) Ltd).

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.